Fexofenadine in Patients With Active Rheumatoid Arthritis
Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Engy Wahsh
- Phone Number: 01003095692
- Email: engywahsh@o6u.edu.eg
Study Contact Backup
- Name: Ahmed Ismaeel
- Phone Number: 01090905827
- Email: hoda_cp@yahoo.com
Study Locations
-
-
-
Banī Suwayf, Egypt
- Recruiting
- Beni-Suef Hospital
-
Contact:
- ahmed
- Phone Number: 01090905827
-
Banī Suwayf, Egypt
- Recruiting
- Faculty of Medicine - Beni Suef Hospital
-
Contact:
- Ahmed, phd
- Phone Number: 01090905827
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Moderate to severe RA (disease activity score-28 joints: DAS-28 > 3.2) were recruited.
- Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
- Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
Exclusion Criteria:
- History of biological DMARDS.
- History/presence of acute heart disease, liver and kidney diseases, COPD
- Intolerance or allergy to fexofenadine or methotrexate
- Alcohol abuse
- Any changes in using medication (changing the dosage or type of medicines
- Receive hormone replacement therapy, warfarin, and other anticoagulants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Fexo group
|
tablet
|
|
Placebo Comparator: Placepo
|
tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ACR 20%
Time Frame: at baseline
|
improvement criteria (ACR20) response rate based on the count of tender/swollen joints,
|
at baseline
|
|
ACR 20%
Time Frame: at week 12
|
improvement criteria (ACR20) response rate based on the count of tender/swollen joints,
|
at week 12
|
|
(HAQDI)
Time Frame: at baseline
|
HAQ-DI (Health Assessment Score- Disability index), in which patients are asked to rate their capacity to perform 20 activities of daily living (ADL).
Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).
For each section the score given to that section is the worst score within the section
|
at baseline
|
|
(HAQDI)
Time Frame: at week 12
|
HAQ-DI (Health Assessment Score- Disability index), in which patients are asked to rate their capacity to perform 20 activities of daily living (ADL).
Scoring within each section is from 0 (without any difficulty) to 3 (unable to do).
For each section the score given to that section is the worst score within the section
|
at week 12
|
|
CRP
Time Frame: at baseline
|
the level of CRP
|
at baseline
|
|
CRP
Time Frame: at week 12
|
the level of CRP
|
at week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TNF-α
Time Frame: at baseline and at week 12
|
Serum level Tumor necrosis factor- alpha (TNF-α)
|
at baseline and at week 12
|
|
IL6
Time Frame: at baseline and at week 12
|
Serum level of IL6
|
at baseline and at week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Joint Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Histamine Antagonists
- Histamine Agents
- Neurotransmitter Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine H1 Antagonists, Non-Sedating
- Fexofenadine
Other Study ID Numbers
Other Study ID Numbers
- FMBSUREC/08052022/Ismaeel
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.